Skip to main content

Stereotaxis Announces First Robotic Magnetic Navigation System in Latvia

Written by Customer Service on . Posted in Public Companies.

  • Pauls Stradiņš Clinical University Hospital installs Genesis Robotic Magnetic Navigation System, establishing the first robotic program for the treatment of cardiac arrhythmia in Latvia
  • First procedures successfully treated patients with a broad range of arrhythmia

ST. LOUIS, Oct. 22, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Pauls Stradiņš Clinical University Hospital in Riga, Latvia, has established the first robotic center for the treatment of cardiac arrhythmias in Latvia and has successfully treated initial patients with the Genesis Robotic Magnetic Navigation System.

“The introduction of the advanced Genesis technology at Pauls Stradiņš Clinical University Hospital reflects the hospital’s long-term commitment to developing highly specialized, modern, and patient safety focused healthcare services,” said Prof. Andrejs Ērglis, Head of the Latvian Cardiology Center at Stradiņš Hospital and Professor of Medicine at the University of Latvia. “We are proud to make this technology available to the benefit of arrhythmia patients, allowing all patients to benefit from the precision, controlled catheter movement, and safety of robotics. We particularly see value in our robotic program expanding the potential to treat complex cardiac arrhythmia.”

Pauls Stradiņš Clinical University Hospital is Latvia’s premier hospital, academic and research center, with a strong reputation in cardiology excellence. The Genesis Robotic Magnetic Navigation system introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmia may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.

“We are delighted to establish this new robotic electrophysiology center of excellence with Pauls Stradiņš Clinical University Hospital,” said David Fischel, Chairman and CEO of Stereotaxis. “We look forward to collaborating with the hospital and cardiology team to advance patient care in Latvia and advance clinical science that will have a global impact.”

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Cautionary Note Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, our overall liquidity and our ability to fund operations, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, our ability to manage and integrate recent acquisitions, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.